294 related articles for article (PubMed ID: 33860688)
1. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
Lubitz CC; Sadow PM; Daniels GH; Wirth LJ
Thyroid; 2021 Oct; 31(10):1451-1462. PubMed ID: 33860688
[No Abstract] [Full Text] [Related]
2. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
3. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
4. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
Romei C; Elisei R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
[TBL] [Abstract][Full Text] [Related]
5. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Patrizio A; Paparo SR; Marone G; Galdiero MR; Guglielmi G; Foddis R; Cristaudo A; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():203-216. PubMed ID: 32569821
[TBL] [Abstract][Full Text] [Related]
6. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
[TBL] [Abstract][Full Text] [Related]
8. Expression of MicroRNAs in Thyroid Carcinoma.
Zhu G; Xie L; Miller D
Methods Mol Biol; 2017; 1617():261-280. PubMed ID: 28540691
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
11. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Filetti S; Durante C; Hartl D; Leboulleux S; Locati LD; Newbold K; Papotti MG; Berruti A;
Ann Oncol; 2019 Dec; 30(12):1856-1883. PubMed ID: 31549998
[No Abstract] [Full Text] [Related]
12. Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg.
Rendl G; Rodrigues M; Schweighofer-Zwink G; Hutter J; Hittmair A; Zellinger B; Hauser-Kronberger C; Pirich C
Wien Klin Wochenschr; 2017 Aug; 129(15-16):540-544. PubMed ID: 28493027
[TBL] [Abstract][Full Text] [Related]
13. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
Bible KC; Ryder M
Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
[TBL] [Abstract][Full Text] [Related]
14. [Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network].
de la Fouchardière C; Wassermann J; Calcagno F; Bardet S; Al Ghuzlan A; Borget I; Borson Chazot F; Do Cao C; Buffet C; Zerdoud S; Decaussin-Petrucci M; Godbert Y; Leboulleux S
Bull Cancer; 2021 Nov; 108(11):1044-1056. PubMed ID: 34593218
[TBL] [Abstract][Full Text] [Related]
15. EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA.
Sherman SI
Trans Am Clin Climatol Assoc; 2019; 130():255-265. PubMed ID: 31516190
[TBL] [Abstract][Full Text] [Related]
16. Expression of Autophagy-Related Proteins in Different Types of Thyroid Cancer.
Kim HM; Kim ES; Koo JS
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257096
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
Abe I; Lam AK
Curr Oncol Rep; 2021 Feb; 23(3):31. PubMed ID: 33582932
[TBL] [Abstract][Full Text] [Related]
18. Gene Fusions in Thyroid Cancer.
Yakushina VD; Lerner LV; Lavrov AV
Thyroid; 2018 Feb; 28(2):158-167. PubMed ID: 29281951
[TBL] [Abstract][Full Text] [Related]
19. Pathology and genetics of thyroid carcinoma.
DeLellis RA
J Surg Oncol; 2006 Dec; 94(8):662-9. PubMed ID: 17131411
[TBL] [Abstract][Full Text] [Related]
20. Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.
San Román Gil M; Pozas J; Molina-Cerrillo J; Gómez J; Pian H; Pozas M; Carrato A; Grande E; Alonso-Gordoa T
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
